Overview

The Effects of Ibandronate or Teriparatide Therapy on Bone Histology and Biochemical Indices in Patients on Hemodialysis With Low Bone Mineral Density

Status:
Terminated

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

Hemodialysis patients with low bone density (total hip T-score <-2.5) will be assigned to receive teriparatide (those with histologic confirmation of adynamic bone disease) or ibandronate (subjects with increased osteoclast number on bone biopsy). Follow-up period: one year. A second bone biopsy at the end of the study.

Phase:

Phase 4

Details

Lead Sponsor:

Papageorgiou General Hospital

Treatments:

Diphosphonates
Ibandronic Acid
Teriparatide